# OnCo record nct06750094 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06750094/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06750094", "NCT06750094" ;
  schema:name "A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy"@en ;
  schema:alternateName "OrigAMI-3"@en ;
  schema:description "A phase 3 trial of Amivantamab, Cetuximab, Bevacizumab and Leucovorin (folinic acid) in colorectal cancer, run by Janssen Research & Development, LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06750094/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06750094> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2024-12-12" ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/cetuximab/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/leucovorin/> ;
  onco:companies <https://onco.cc/companies/johnson-johnson/> .